Pages

▼
Monday, March 31, 2008

Tekmira and Protiva Reunification Forms Leading RNAi Therapeutics Delivery Company

›
[Corrections/clarifications following Tekmira conference call: Apparently, the new company has also exercised an InterfeRx pick for the Apo...
4 comments:

Day 4 of the RNAi Keystone Conference

›
As I alluded to already in my previous post on the conference, the issue of transcriptional gene silencing (TGS) mediated by RNAi-related me...
Friday, March 28, 2008

Day 2 and 3 of Keystone RNAi Conference

›
The Keystone conference kept me kind of busy, so I did not find the time to summarize what’s been happening here in the mountains up Vancouv...
1 comment:
Thursday, March 27, 2008

Journal Club: Study Shows TLR3 Induction by siRNAs with Anti-angiogenic Effects, Questioning Ongoing RNAi Clinical Trials for Wet AMD

›
RNAi is a relatively young therapeutic platform and we are rapidly learning about the gene-specific and non-specific effects of RNAi trigger...
4 comments:
Wednesday, March 26, 2008

Day 1 of Keystone RNAi Conference: New Small RNAs and Oral RNAi Delivery

›
More recently discovered types of small RNAs were the focus of the keynote session on the first night of the influential annual gathering of...
3 comments:
Sunday, March 16, 2008

A Framework for Progressing RNAi Therapeutics into the Clinic

›
This week was quite busy for the RNAi Therapeutics space with important corporate developments for CytRx/RXi (succesful spin-out/IPO), Naste...
3 comments:
Wednesday, March 12, 2008

Dharmacon’s Accell Delivery Technology Signals Increasing Focus on non-Endosomal siRNA Uptake Strategies

›
[Update May 8, 2008: Based on a recent patent application by Dharmacon, WO 2008/036825, it appears that Accell siRNAs are in fact very simil...
5 comments: